Literature DB >> 23980088

Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.

Robin K Kelley1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23980088     DOI: 10.1200/JCO.2013.49.7941

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Chiun Hsu; Bang-Bin Chen; Chien-Hung Chen; Ming-Chih Ho; Jason Chia-Hsien Cheng; Norihiro Kokudo; Takamichi Murakami; Winnie Yeo; Jinsil Seong; Ji-Dong Jia; Kwan-Hyub Han; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

2.  Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.

Authors:  Jianxin Chen; Junhui Wang; Fangwei Xie
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.